【摘要】：目的:探討替米沙坦聯(lián)合干擾素治療對慢性乙肝患者肝纖維化的影響。方法:選取既往未行抗病毒治療的HBVDNA陽性的慢性乙肝患者50例,隨機分為觀察組及對照組。對照組予以普通干擾素治療,觀察組在普通干擾素治療的基礎上加用替米沙坦80 mg口服,每日一次。治療周期48周。治療前后分別行血清肝纖維化指標及肝臟組織病理學檢查,并通過免疫組化方法測定TGF-β1、TIMP-1、MMP-1及α-SMA的表達及含量。結果:治療后,觀察組及對照組血清肝纖維化指標(HA、Ⅳ-C、LN、PIIIP)、肝纖維化分級水平及肝纖維化半定量計分較治療前均下降,且觀察組下降更明顯,治療前后,觀察組和對照組肝組織中TGF-β1、TIMP-1及α-SMA表達水平明顯下降,MMP-1水平明顯升高,以觀察組變化更為顯著。結論:干擾素抗病毒的同時有抗肝纖維化作用,加用替米沙坦后抗肝纖維化作用更明顯,提示替米沙坦與干擾素有協(xié)同抗纖維化作用。
[Abstract]:Objective: to investigate the effect of telmisartan combined with interferon on hepatic fibrosis in patients with chronic hepatitis B. Methods: 50 patients with HBVDNA positive hepatitis B were randomly divided into observation group and control group. The control group was treated with common interferon, and the observation group was treated with telmisartan 80 mg orally once a day. The treatment period was 48 weeks. Serum hepatic fibrosis index and liver histopathology were examined before and after treatment, and the expression and content of MMP-1 and 偽-SMA in TGF- 尾 1 TIMP-1 and 偽-SMA were determined by immunohistochemical method. Results: after treatment, serum hepatic fibrosis index (HA, 鈪，

本文編號：2414156